Streptococcus Pneumoniae Infection
12
0
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
25%
3 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.
Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
A Controlled Human Pneumococcal Infection Model (PIM) Study
Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala
Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus
Pneumococcal Nasopharyngeal Colonization as Predictor of Community-Acquired Pneumonia (CAP) in Adults With Chronic Diseases.
Understanding Pneumococcal Carriage and Disease 2017-2020
Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
Effect of Two Versus Three Pneumococcal Conjugate Vaccinations